Browse studies

Find your next paid study

37 recruiting studies matching your filters

Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)

* To find the recommended dose of axatilimab given alone and in combination with ruxolitinib in patients with MF and CMML. * To learn if axatilimab given in co…

Myelofibrosis (MF)Chronic Myelomonocytic Leukemia (CMML)

Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT07128381